Eli Lilly & Co. (NYSE: LLY) announced that it will cease development of basal insulin peglispro (BIL), a potential treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE